Trial Profile

Phase II Study of Cetuximab and Bevacizumab in Esophageal Carcinoma That Failed First Line Therapy

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 26 Nov 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Cetuximab (Primary)
Indications Oesophageal cancer
Focus Therapeutic Use

Most Recent Events

07 Oct 2008 Actual start date changed from Mar 2008 to Oct 2008 as reported by CT.gov
07 Oct 2008 Status changed from recruiting to withdrawn prior to recruitment as reported by CT.gov
16 Apr 2008 New trial record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com